0001933414-24-000032.txt : 20240620
0001933414-24-000032.hdr.sgml : 20240620
20240620174401
ACCESSION NUMBER: 0001933414-24-000032
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240617
FILED AS OF DATE: 20240620
DATE AS OF CHANGE: 20240620
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Congleton Jon
CENTRAL INDEX KEY: 0001644975
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-41614
FILM NUMBER: 241057652
MAIL ADDRESS:
STREET 1: 3122 STERLING CIRCLE, SUITE 200
CITY: BOULDER
STATE: CO
ZIP: 80301
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Mineralys Therapeutics, Inc.
CENTRAL INDEX KEY: 0001933414
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 150 N. RADNOR CHESTER ROAD
STREET 2: SUITE F200
CITY: RADNOR
STATE: PA
ZIP: 19087
BUSINESS PHONE: (888) 378-6240
MAIL ADDRESS:
STREET 1: 150 N. RADNOR CHESTER ROAD
STREET 2: SUITE F200
CITY: RADNOR
STATE: PA
ZIP: 19087
4
1
wk-form4_1718919832.xml
FORM 4
X0508
4
2024-06-17
0
0001933414
Mineralys Therapeutics, Inc.
MLYS
0001644975
Congleton Jon
150 N. RADNOR CHESTER ROAD,
SUITE F200
RADNOR
PA
19087
1
1
0
0
Chief Executive Officer
1
Common Stock
2024-06-17
4
S
0
17766
12.2544
D
958505
D
Common Stock
2024-06-18
4
S
0
16607
11.9873
D
941898
D
Common Stock
2024-06-20
4
S
0
14940
11.7294
D
926958
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 30, 2024.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $12.0982 to $12.4627. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $11.76 to $12.12.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $11.525 to $12.05.
/s/ Adam Levy, Attorney-in-fact
2024-06-20